105 related articles for article (PubMed ID: 38945824)
1. Dual-Targeting of the HER2 Cancer Receptor with an Antibody-Directed Enzyme and a Nanobody-Guided MMAE Prodrug Scaffold.
Smidt JM; Märcher A; Skaanning MK; El-Chami K; Teodori L; Omer M; Kjems J; Gothelf KV
Chembiochem; 2024 Jun; ():e202400437. PubMed ID: 38945824
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy.
Cho H; Shim MK; Moon Y; Song S; Kim J; Choi J; Kim J; Lee Y; Park JY; Kim Y; Ahn CH; Kim MR; Yoon HY; Kim K
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297566
[TBL] [Abstract][Full Text] [Related]
4. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
5. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
[TBL] [Abstract][Full Text] [Related]
6. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
7. Complementation Dependent Enzyme Prodrug Therapy Enables Targeted Activation of Prodrug on HER2-Positive Cancer Cells.
Nervig CS; Hatch ST; Owen SC
ACS Med Chem Lett; 2022 Nov; 13(11):1769-1775. PubMed ID: 36385932
[TBL] [Abstract][Full Text] [Related]
8. Antibody-directed enzyme prodrug therapy (ADEPT): a review.
Springer CJ; Niculescu-Duvaz I
Adv Drug Deliv Rev; 1997 Jul; 26(2-3):151-172. PubMed ID: 10837540
[TBL] [Abstract][Full Text] [Related]
9. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
[TBL] [Abstract][Full Text] [Related]
10. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
[TBL] [Abstract][Full Text] [Related]
11. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
12. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.
Afshar S; Olafsen T; Wu AM; Morrison SL
J Exp Clin Cancer Res; 2009 Dec; 28(1):147. PubMed ID: 19958550
[TBL] [Abstract][Full Text] [Related]
15. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases.
Yap ML; McFadyen JD; Wang X; Ziegler M; Chen YC; Willcox A; Nowell CJ; Scott AM; Sloan EK; Hogarth PM; Pietersz GA; Peter K
Theranostics; 2019; 9(4):1154-1169. PubMed ID: 30867822
[No Abstract] [Full Text] [Related]
16. Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.
Juen L; Baltus CB; Gély C; Kervarrec T; Feuillâtre O; Desgranges A; Viaud-Massuard MC; Martin C
Bioconjug Chem; 2022 Feb; 33(2):418-426. PubMed ID: 35104102
[TBL] [Abstract][Full Text] [Related]
17. Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.
Damiani I; Castiglioni S; Sochaj-Gregorczyk A; Bonacina F; Colombo I; Rusconi V; Otlewski J; Corsini A; Bellosta S
Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34439990
[TBL] [Abstract][Full Text] [Related]
18. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
Sharma SK; Bagshawe KD
Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
[TBL] [Abstract][Full Text] [Related]
19. An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.
Hui X; Yuan C; Cao W; Ge W; Zhang D; Dan M; Zhao Q; Liu B; Yao B
Onco Targets Ther; 2022; 15():331-343. PubMed ID: 35422630
[TBL] [Abstract][Full Text] [Related]
20. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]